文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

骨髓增生异常综合征患者的单倍体移植

Haploidentical transplant in patients with myelodysplastic syndrome.
PubMed 文献 · Blood Adv · 2017-09-27

该研究报道了欧洲血液与骨髓移植组2007至2014年间228例接受HLA不合相关供者移植的MDS患者资料,中位年龄56岁,84例(37%)移植时已转化为急性髓系白血病。使用移植后环磷酰胺(PT-CY)者3年总生存为38%,未使用者为28%;多因素分析显示预处理强度和PT-CY使用是主要风险因素。

要点

  • 228例MDS患者接受单倍体移植,中位年龄56岁,37%移植时已转化为急性髓系白血病。
  • PT-CY组3年总生存38%,未用PT-CY组28%;非复发死亡率分别为41%和55%。
  • 多因素分析显示预处理强度和PT-CY使用是主要风险因素。

核心结论

  • MDS患者接受单倍体移植的结局接近其他HLA不合供者移植的结果,约三分之一患者移植后3年无病生存。
  • 使用PT-CY可能改善MDS单倍体移植患者的结局。

研究设计与样本

  • 欧洲血液与骨髓移植组(EBMT)活动报告,纳入2007年至2014年间接受HLA不合相关供者移植的228例MDS患者。
  • 中位移植年龄56岁;84例(37%)移植时MDS已转化为急性髓系白血病。
  • 34例接受体外T细胞去除;194例接受T细胞充足移植,其中102例使用移植后环磷酰胺(PT-CY)预防移植物抗宿主病(GVHD)。

主要发现

  • PT-CY组与其他患者急性GVHD累积发生率分别为25%与37%,慢性GVHD累积发生率分别为37%与24%。
  • 非复发死亡率在未使用PT-CY组为55%,在PT-CY组为41%。
  • 3年总生存率在未使用PT-CY组为28%,在PT-CY组为38%。
  • 多因素分析显示主要风险因素为预处理强度和PT-CY的使用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option. The present study reports the European Group for Blood and Marrow Transplantation activity for haploidentical transplantation in MDS patients. A total of 228 patients transplanted from a mismatched HLA-related donor between 2007 and 2014 were studied. The median age at transplant was 56 years. Eighty-four (37%) patients had MDS transformed into acute myeloid leukemia at the time of transplant. Ex vivo T-cell depletion was used in 34 patients. One hundred ninety-four patients received a T-cell replete transplant and 102 patients received posttransplant cyclophosphamide (PT-CY) as graft-versus-host disease (GVHD) prophylaxis. The cumulative incidences of acute and chronic GVHD in PT-CY vs other patients were 25% vs 37% and 37% vs 24%, respectively. The cumulative incidence of nonrelapse mortality was 55% in patients who did not receive PT-CY (no PT-CY) and 41% in patients who did receive PT-CY. Three-year overall survival was 28% in no PT-CY patients and 38% in PT-CY patients. In multivariable analysis, the main risk factors were the intensity of the conditioning regimen and the use of PT-CY. In conclusion, the outcomes of MDS patients who received an haploidentical transplant are close to the results other transplantations from HLA-mismatched donors with approximately one-third of patients alive and free of disease 3 years after transplant, and the use of PT-CY may improve their outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Robin M, Porcher R, Ciceri F, et al. Haploidentical transplant in patients with myelodysplastic syndrome. Blood Adv. 2017. PMID: 29296834. doi:10.1182/bloodadvances.2017007146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。